Acute coronary syndromes: A focus on thrombin

Journal of Invasive Cardiology

Volumn 14, Issue SUPPL. B, 2002, Pages

  Weitz, Jeffrey I ^a   Bates, Shannon M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; THROMBIN; THROMBIN INHIBITOR;

ACUTE DISEASE; BLEEDING; CORONARY ARTERY THROMBOSIS; HEART MUSCLE ISCHEMIA; HUMAN; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA;

ACUTE DISEASE; ANTICOAGULANTS; BLOOD COAGULATION; CORONARY DISEASE; CORONARY THROMBOSIS; FORECASTING; HEPARIN; HUMANS; PLATELET ACTIVATION; SYNDROME; THROMBIN; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0036222922     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patents
3. Unfractionated heparin and low-molecular-weight heparin in unstable angina and acute coronary syndromes without ST elevation: A meta-analysis
4. An international trial comparing four thrombolytic strategies for acute myocardial infarction
5. Long-term management of unstable angina and non-Q-wave myocardial infarction
6. Blood-borne tissue factor: Another view of thrombosis
7. Molecular and cellular biology of blood coagulation
8. How the protease thrombin talks to cells
9. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation
10. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
11. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation
12. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus
13. Thrombin signaling and protease-activated receptors
14. Role of thrombin signaling in platelets in haemostasis and thrombosis
15. Heparin
16. Thrombin generation and inactivation in the presence of antithrombin III and heparin
17. The use of prothrombin (S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation
18. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
19. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-dependent inhibitors
20. Importance of factor Xa in determining the procoagulant activity of whole-blood clots
21. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II
22. Human thrombi contain an abundance of active thrombin
23. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity
24. The influence of fibrinogen and fibrin on thrombin generation - Evidence for feedback activation of the clotting system by clot bound thrombin
25. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway
26. Biologic rationale for the therapeutic role of specific antithrombins
27. Direct thrombin inhibitors in acute coronary syndromes: Present and future
28. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
29. Hirudins: From leeches to man
30. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
31. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
32. Kinetic mechanism for the interaction of hirulog with thrombin
33. The use of bivalirudin in patients with renal impairment
34. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor
35. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
36. Direct thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data
37. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
38. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty study
39. Clinical outcomes of bivalirudin for ischemic heart disease
40. New anticoagulant drugs
41. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
42. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery